Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics, Inc. (GRTX)
:GRTX
Total Valuation
Galera Therapeutics has a market cap or net worth of $1.81M. The enterprise value is $149.67M.
Market Cap$1.81M
Enterprise Value$149.67M
Share Statistics
Galera Therapeutics has 75,462,390 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,462,390
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Galera Therapeutics’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is -220.25%.
Return on Equity (ROE)0.45
Return on Assets (ROA)-2.26
Return on Invested Capital (ROIC)-220.25%
Return on Capital Employed (ROCE)-2.22
Revenue Per Employee0.00
Profits Per Employee-19.69M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galera Therapeutics is -0.11. Galera Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.11
PS Ratio0.00
PB Ratio-0.05
Price to Fair Value-0.05
Price to FCF-0.14
Price to Operating Cash Flow-0.14
PEG Ratio<0.01
Income Statement
In the last 12 months, Galera Therapeutics had revenue of 0.00 and earned -59.08M in profits. Earnings per share was -1.33.
Revenue0.00
Gross Profit-259.00K
Operating Income-46.95M
Pretax Income-59.08M
Net Income-59.08M
EBITDA-46.69M
Earnings Per Share (EPS)-1.33
Cash Flow
In the last 12 months, operating cash flow was -9.91M and capital expenditures -9.00K, giving a free cash flow of -9.92M billion.
Operating Cash Flow-9.91M
Free Cash Flow-9.92M
Free Cash Flow per Share-0.13
Dividends & Yields
Galera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.17
52-Week Price Change-88.24%
50-Day Moving Average0.03
200-Day Moving Average0.05
Relative Strength Index (RSI)38.60
Average Volume (3m)107.73K
Important Dates
Galera Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Galera Therapeutics as a current ratio of 4.36, with Debt / Equity ratio of 0.00%
Current Ratio4.36
Quick Ratio4.36
Debt to Market Cap0.17
Net Debt to EBITDA0.36
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Galera Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galera Therapeutics EV to EBITDA ratio is 0.23, with an EV/FCF ratio of 0.23.
EV to Sales0.00
EV to EBITDA0.23
EV to Free Cash Flow0.23
EV to Operating Cash Flow0.23
Balance Sheet
Galera Therapeutics has $8.46M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$8.46M billion.
Cash & Marketable Securities$8.46M
Total Debt$0.00
Net Cash-$8.46M
Net Cash Per Share-$0.11
Tangible Book Value Per Share-$3.02
Margins
Gross margin is -154.55%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-154.55%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galera Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast75.56%